Colds are caused by seasonal coronaviruses (CoVs) and previous studies have suggested that exposure to cold coronaviruses may safeguard against the SARS-CoV-2 coronavirus that causes COVID-19.
To find out if that was true, researchers analyzed blood samples collected from hundreds of people before the COVID-19 pandemic.
More than 20% of the samples had CoV antibodies that could theoretically bind to both cold-causing CoVs and to key sites on SARS-CoV-2.
However, these antibodies didn’t reduce SARS-CoV-2 infectivity, and weren’t associated with better outcomes in people who later got COVID-19, according to the study published online Feb. 9 in the journal Cell.
The researchers also tested blood from different groups of people and found that, on average, both children and adults tend to have similar levels of CoV antibodies.
This suggests that these antibodies aren’t the reason why most children don’t develop severe COVID-19, the study authors concluded.
“We found that many people possessed antibodies that could bind to SARS-CoV-2 before the pandemic, but these antibodies could not prevent infections,” said study leader Scott Hensley. He’s an associate professor of microbiology at the University of Pennsylvania’s School of Medicine, in Philadelphia.
“Although antibodies from prior coronavirus infections cannot prevent SARS-CoV-2 infections, it is possible that pre-existing memory B cells and T cells could potentially provide some level of protection or at least reduce the disease severity of COVID-19. Studies need to be completed to test that hypothesis,” Hensley said in a university news release.
Larger studies are required to definitively answer the question of whether pre-existing anti-CoV antibodies can protect against SARS-CoV-2 viruses, the researchers said.
But one expert welcomed the findings.
“The idea that having the snuffles a while back somehow protects you from SARS-CoV-2 infection has always left me cold, but it’s been a persistent urban legend throughout the pandemic,” Dr. John Moore, a virologist at Weill Cornell Medicine in New York City, told The New York Times. “Hopefully, this new paper will finally cool everyone down and put such thoughts into the freezer.”
The researchers did say that more studies are needed to assess other types of immune response (such as T cells) to seasonal colds to determine if they provide some amount of cross-reactive protection against COVID-19.
Since the pandemic began more than a year ago, there have been more than 107 million reported infections and more than 2.3 million deaths reported worldwide.
Some risk factors for severe COVID-19 are clear — such as age — but it’s still not fully understood why some people have mild illness or no symptoms while others become seriously ill. Experts believe that antibodies may be one possible explanation.
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Further Support and Information on COVID-19
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022